The increasing prevalence of mental health disorders and the growing adoption of digital health technologies are driving the expansion of the psychiatric digital biomarkers market.
The global psychiatric digital biomarkers market was valued at USD 630.40 million in 2024 and is projected to grow from USD 782.65 million in 2025 to USD 5,543.77 million by 2034, exhibiting a compound annual growth rate (CAGR) of 24.3% during the forecast period from 2025 to 2034. This rapid growth can be attributed to the rising awareness of mental health issues, advancements in digital health technologies, and the increasing adoption of digital biomarkers in psychiatric research and clinical practice.
Market Overview
Psychiatric digital biomarkers are measurable biological, physiological, or behavioral data captured through digital devices and used to assess and monitor mental health conditions. These biomarkers are collected using various technologies, such as wearable devices, mobile applications, and sensors, to provide objective, real-time insights into an individual’s mental state. By enabling continuous monitoring and personalized care, psychiatric digital biomarkers offer the potential to revolutionize the diagnosis, treatment, and management of mental health disorders.
Key Growth Drivers
- Rising Prevalence of Mental Health Disorders Mental health conditions, including depression, anxiety, bipolar disorder, schizophrenia, and post-traumatic stress disorder (PTSD), have become increasingly prevalent worldwide. According to the World Health Organization (WHO), nearly 1 in 4 people will be affected by mental or neurological disorders at some point in their lives. As the global burden of mental health disorders continues to rise, the demand for innovative tools, such as psychiatric digital biomarkers, to monitor, diagnose, and treat these conditions is increasing.
- Advancements in Digital Health Technologies The development of digital health technologies, including wearable devices, smartphone apps, and sensors, has significantly advanced the field of psychiatric digital biomarkers. These technologies enable continuous, real-time data collection, offering clinicians valuable insights into patients’ mental health status. For example, wearable devices can monitor sleep patterns, physical activity, and physiological responses, while mobile apps can track mood changes, behavior, and cognitive performance. This increased availability of digital health tools is propelling market growth.
- Shift Towards Personalized Healthcare There is a growing trend towards personalized healthcare and precision medicine in the psychiatric field. Digital biomarkers play a critical role in tailoring treatment plans to the specific needs of individual patients. By providing objective data that reflects an individual’s mental health status, these biomarkers enable clinicians to adjust therapies based on real-time information, improving treatment outcomes and patient satisfaction. The shift towards personalized approaches is driving the demand for psychiatric digital biomarkers.
- Integration of Artificial Intelligence and Machine Learning The integration of artificial intelligence (AI) and machine learning (ML) with psychiatric digital biomarkers is transforming the way mental health conditions are diagnosed and monitored. AI algorithms can analyze large datasets generated by digital biomarkers to identify patterns, predict disease progression, and recommend optimal treatment options. This ability to analyze complex data and provide predictive insights is enhancing the effectiveness of psychiatric digital biomarkers and is expected to drive further market expansion.
- Government Initiatives and Funding Governments and healthcare organizations around the world are increasingly focusing on improving mental health care and funding digital health initiatives. For example, the U.S. Food and Drug Administration (FDA) has begun approving digital therapeutics and tools for mental health applications, which is opening the door for the adoption of psychiatric digital biomarkers in clinical practice. Additionally, public and private sector investments in mental health technologies are fueling market growth and innovation in the space.
Market Challenges
- Data Privacy and Security Concerns The collection and use of sensitive health data for psychiatric digital biomarkers raise significant privacy and security concerns. Patients’ mental health data is highly personal, and there is a need for stringent regulations and security measures to protect this data from unauthorized access, breaches, or misuse. Ensuring compliance with data protection regulations, such as the General Data Protection Regulation (GDPR) in Europe and the Health Insurance Portability and Accountability Act (HIPAA) in the U.S., is essential for the widespread adoption of psychiatric digital biomarkers.
- Regulatory and Standardization Issues While digital health tools, including psychiatric digital biomarkers, offer significant potential, the lack of standardized guidelines and regulatory frameworks presents challenges to their widespread adoption. Governments and regulatory bodies need to establish clear standards for the validation, approval, and use of psychiatric digital biomarkers in clinical practice. Without these frameworks, healthcare providers and patients may be hesitant to adopt these technologies.
- Limited Awareness and Adoption in Certain Regions While awareness of psychiatric digital biomarkers is growing in developed regions like North America and Europe, adoption rates in developing regions remain relatively low. Limited access to healthcare infrastructure, technology, and digital literacy can hinder the widespread adoption of psychiatric digital biomarkers in low-resource settings. Efforts to increase awareness, improve digital infrastructure, and reduce disparities in healthcare access will be essential for expanding the market in these regions.
Market Segmentation
By Product Type:
- Wearable Devices
- Mobile Applications
- Sensors and Monitoring Devices
The wearable devices segment is expected to dominate the market due to the increasing use of wearable technologies such as smartwatches and fitness trackers to monitor mental health conditions. These devices are capable of tracking physiological parameters such as heart rate, sleep patterns, and physical activity, providing valuable insights into a patient’s mental state.
By Application:
- Depression
- Anxiety
- Bipolar Disorder
- Schizophrenia
- Post-Traumatic Stress Disorder (PTSD)
- Others
Depression is expected to be the largest application segment, as it is one of the most common mental health disorders worldwide. Digital biomarkers offer a non-invasive and cost-effective way to monitor mood changes, identify early signs of depression, and evaluate treatment efficacy.
By End-User:
- Hospitals
- Clinics
- Research Institutions
- At-Home Healthcare
The hospital and clinical settings will account for the largest share of the psychiatric digital biomarkers market. These settings have the infrastructure and resources to implement and monitor digital health technologies, enabling clinicians to utilize digital biomarkers in diagnosis and treatment.
Regional Analysis
North America
North America is expected to hold the largest market share during the forecast period, driven by the high prevalence of mental health disorders, advancements in digital health technologies, and strong healthcare infrastructure. The United States is the primary contributor to market growth, with a large number of digital health companies and government initiatives supporting mental health care.
Europe
Europe is another key market for psychiatric digital biomarkers, with countries like the United Kingdom, Germany, and France leading the way. The region’s focus on mental health, coupled with investments in digital health, is expected to support the market’s growth.
Asia-Pacific
The Asia-Pacific region is expected to witness the highest growth rate during the forecast period. The increasing adoption of digital health technologies, rising awareness of mental health issues, and improving healthcare infrastructure in countries like China, India, and Japan are driving the demand for psychiatric digital biomarkers.
Rest of the World
In regions such as Latin America and Middle East & Africa, the market is expected to grow steadily, with increasing interest in mental health and digital health technologies. However, challenges such as limited healthcare infrastructure and resources may slow adoption in these regions.
Competitive Landscape
Key players in the psychiatric digital biomarkers market include:
-
- Biogen
- Brainomix
- Clario
- Empatica Inc.
- Huma
- IXICO plc
- Koneksa Health
- PureTech Health PLC
- Sonde Health, Inc.
- VivoSense
These companies are focusing on expanding their product portfolios, forming strategic partnerships, and leveraging AI and machine learning to enhance the accuracy and effectiveness of psychiatric digital biomarkers.
Conclusion
The psychiatric digital biomarkers market is poised for significant growth, reaching USD 5,543.77 million by 2034, driven by the increasing prevalence of mental health disorders, advancements in digital health technologies, and the growing demand for personalized treatment approaches. As digital health technologies continue to evolve, psychiatric digital biomarkers will play an increasingly important role in the diagnosis, treatment, and management of mental health conditions, offering valuable opportunities for healthcare providers, technology developers, and investors in the market.
More Trending Latest Reports By Polaris Market Research:
Remote Sensing Services Market
Medical Suction Devices Market
Ddos Protection And Mitigation Security Market
